Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag studyHochmair, Maximilian J (Avtor) Morabito, Alessandro (Avtor) Hao, Desiree (Avtor) Yang, Cheng-Ta (Avtor) Soo, Ross A (Avtor) Yang, James C-H (Avtor) Gucalp, Rasim (Avtor) Halmos, Balazs (Avtor) Wang, Lara (Avtor) Märten, Angela (Avtor) Čufer, Tanja (Avtor) non-small cell lung carcinoma - therapydrug therapyafatinibosimertinibGioTag studyAims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.Future Medicine Ltd20192020-09-11 14:42:57Neznano12417UDK: 616.2ISSN pri članku: 1744-8301DOI: 10.2217/fon-2019-0346COBISS_ID: 2048610929OceCobissID: 521824025sl© 2019 Maximilian J Hochmair